Secondary infection of common skin conditions including eczema: antimicrobial prescribing
In development [GID-NG10135] Expected publication date: 02 March 2021
Search results
715 results
-
-
Percutaneous insertion of a closure device to repair a paravalvular leak around a replaced mitral or aortic valve: interventional procedure consultation
We are listening to your views on this interventional procedures guidance. Comments close 25 February 2021.
-
Synthetic cartilage implant insertion for first metatarsophalangeal joint osteoarthritis (hallux rigidus): interventional procedure consultation
We are listening to your views on this interventional procedures guidance. Comments close 25 February 2021.
-
Stye: antimicrobial prescribing
In development [GID-NG10167] Expected publication date: TBC
-
Blepharitis: antimicrobial prescribing
In development [GID-NG10168] Expected publication date: TBC
-
Skin abscess: antimicrobial prescribing
In development [GID-NG10163] Expected publication date: TBC
-
Conjunctivitis: antimicrobial prescribing
In development [GID-NG10166] Expected publication date: TBC
-
Clostridioides difficile infection: antimicrobial prescribing
In development [GID-NG10144] Expected publication date: 23 July 2021
-
Betibeglogene autotemcel for treating transfusion-dependent beta-thalassaemia [ID968]: appraisal consultation
We are listening to your views on this technology appraisal guidance. Comments close 04 March 2021.
-
Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy [ID2727]: appraisal consultation
We are listening to your views on this technology appraisal guidance. Comments close 05 March 2021.
-
Mexiletine for treating myotonia in adults with non-dystrophic myotonic disorders ID1488: appraisal consultation
We are listening to your views on this technology appraisal guidance. Comments close 05 March 2021.
-
Cytoreduction surgery with hyperthermic intraoperative peritoneal chemotherapy for peritoneal carcinomatosis
In development [GID-IPG10138] Expected publication date: 03 March 2021
-
Free-functioning gracilis transfer to restore upper limb function in brachial plexus injury
In development [GID-IPG10146] Expected publication date: 03 March 2021
-
Multiple myeloma - lenalidomide (maintenance, post autologous stem cell transplantation) [ID475]
In development [GID-TAG430] Expected publication date: 03 March 2021
-
Baricitinib for treating moderate to severe atopic dermatitis [ID1622]
In development [GID-TA10562] Expected publication date: 03 March 2021
-
Pembrolizumab with docetaxel for treating hormone-relapsed metastatic prostate cancer untreated with chemotherapy [ID3801]
Proposed [GID-TA10668] Expected publication date: TBC
-
Eryaspase with chemotherapy for previously treated advanced or metastatic pancreatic cancer [ID3781]
Proposed [GID-TA10637] Expected publication date: TBC
-
Naxitamab with GM-CSF for treating relapsed or refractory high-risk neuroblastoma [ID3769]
Proposed [GID-TA10638] Expected publication date: TBC
-
Remdesivir for treating COVID-19 [ID3808]
Proposed [GID-TA10721] Expected publication date: TBC
-
Treosulfan with fludarabine before allogeneic stem cell transplant for people aged under 18 with non-malignant diseases [ID3745]
Proposed [GID-TA10599] Expected publication date: TBC
-
Cabotegravir with rilpivirine for the oral treatment of HIV-1 [ID3731]
Proposed [GID-TA10604] Expected publication date: TBC
-
STG320 for treating persistent allergic rhinitis caused by house dust mites (ID1278)
Proposed [GID-TA10279] Expected publication date: TBC
-
Tocilizumab for treating systemic sclerosis (ID1396)
Proposed [GID-TA10346] Expected publication date: TBC
-
Intravenous zanamivir for treating influenza in hospital [ID1196]
Proposed [GID-TA10298] Expected publication date: TBC
-
Bupivacaine–meloxicam for treating postoperative pain [ID2728]
Proposed [GID-TA10716] Expected publication date: TBC
-
Mepolizumab for treating hypereosinophilic syndrome [ID3749]
Proposed [GID-TA10755] Expected publication date: TBC
-
Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (CDF review of TA505) [ID1635]
Proposed [GID-TA10781] Expected publication date: 22 September 2021
-
Empagliflozin for treating chronic heart failure with reduced ejection fraction [ID3826]
Proposed [GID-TA10719] Expected publication date: TBC
-
Palbociclib for treating high-risk early breast cancer after neoadjuvant chemotherapy [ID3846]
Proposed [GID-TA10723] Expected publication date: TBC
-
Daratumumab in combination for untreated multiple myeloma when high-dose chemotherapy with stem cell transplant is unsuitable [ID3843]
Proposed [GID-TA10726] Expected publication date: TBC
-
Netarsudil for treating open angle glaucoma or ocular hypertension [ID1078]
Proposed [GID-TA10431] Expected publication date: TBC
-
Nivolumab with chemotherapy for neoadjuvant treatment of early non-small-cell lung cancer [ID3757]
Proposed [GID-TA10632] Expected publication date: TBC
-
Dapagliflozin for treating chronic kidney disease [ID3866]
Proposed [GID-TA10808] Expected publication date: TBC
-
Avatrombopag in combination for treating chronic immune thrombocytopenia [ID3838]
Proposed [GID-TA10738] Expected publication date: TBC
-
Burosumab for treating X-linked hypophosphataemia in adults [ID3822]
Proposed [GID-TA10733] Expected publication date: TBC
-
Ibrutinib with corticosteroids for untreated chronic graft versus host disease [ID3792]
Proposed [GID-TA10722] Expected publication date: TBC
-
Sarizotan for the treatment of respiratory symptoms associated with Rett syndrome [ID1506]
Proposed [GID-TA10662] Expected publication date: TBC
-
Nivolumab with ipilimumab for untreated PD-L1 positive unresectable or metastatic urothelial cancer [ID3829]
Proposed [GID-TA10707] Expected publication date: TBC
-
Rigosertib for previously treated high-risk myelodysplastic syndrome [ID805]
Proposed [GID-TA10709] Expected publication date: TBC
-
Durvalumab with tremelimumab and chemotherapy for treating unresectable or advanced urothelial cancer [ID3855]
Proposed [GID-TA10748] Expected publication date: TBC
-
Azacitidine for treating relapsed or refractory angioimmunoblastic T-cell lymphoma [ID3864]
Proposed [GID-TA10750] Expected publication date: TBC
-
Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer [ID3852 ]
Proposed [GID-TA10751] Expected publication date: TBC
-
Lifileucel for previously treated unresectable or metastatic melanoma [ID3863]
Proposed [GID-TA10752] Expected publication date: TBC
-
Nivolumab for adjuvant treatment of high-risk hepatocellular carcinoma after liver resection or ablation [ID3858]
Proposed [GID-TA10745] Expected publication date: TBC
-
Ibrutinib with venetoclax for untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID3860]
Proposed [GID-TA10746] Expected publication date: TBC
-
Pembrolizumab with chemotherapy then olaparib maintenance for treating BRCA-negative advanced epithelial ovarian, fallopian tube or peritoneal cancer [ID3853]
Proposed [GID-TA10747] Expected publication date: TBC
-
Sotagliflozin for treating type 2 diabetes [ID1657]
Proposed [GID-TA10665] Expected publication date: TBC
-
Imlifidase for preventing kidney transplant rejection in people with chronic kidney disease [ID1672]
Proposed [GID-TA10552] Expected publication date: TBC
-
Dusquetide for treating oral mucositis during chemoradiation for head and neck cancer [ID3830]
Proposed [GID-TA10715] Expected publication date: TBC
-
Etrolizumab for treating moderately to severely active ulcerative colitis [ID3827]
Proposed [GID-TA10717] Expected publication date: TBC